- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
59 result(s) found for: Tau protein.
Displaying page 1 of 3.
EudraCT Number: 2019-004634-41 | Sponsor Protocol Number: IIBSP-FPI-2019-108 | Start Date*: 2021-08-25 |
Sponsor Name:Institut de Recerca HSCSP | ||
Full Title: Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome | ||
Medical condition: Taupathies | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000473-83 | Sponsor Protocol Number: PET-tau-FACEHBI | Start Date*: 2021-12-15 |
Sponsor Name:Fundació ACE-Institut Català de Neurociències Aplicades | ||
Full Title: PET imaging study of the brain tau deposit in individuals with subjective cognitive decline and mild cognitive impairment: FACEHBI cohort. | ||
Medical condition: Subjective cognitive impairment and mild cognitive decline in evaluation for diagnosis of Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003473-94 | Sponsor Protocol Number: UCL-2016-121 | Start Date*: 2019-05-20 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. | ||
Medical condition: Alzheimer’s disease (AD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004656-22 | Sponsor Protocol Number: IIBSP-THK-2015-77 | Start Date*: 2017-10-10 |
Sponsor Name:Institut de Recerca HSCSP | ||
Full Title: Pilot study of the [18F]THK-5351 positron emission tomography (PET) tracer in different tauopathies. | ||
Medical condition: Taupatías | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005542-38 | Sponsor Protocol Number: MK-8931-019 | Start Date*: 2014-03-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., | |||||||||||||
Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment... | |||||||||||||
Medical condition: prodromal Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001436-35 | Sponsor Protocol Number: COFITAGE2016 | Start Date*: 2017-01-06 |
Sponsor Name:Service of Neurology, CHU Liege | ||
Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population | ||
Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003552-36 | Sponsor Protocol Number: COG0202 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease | |||||||||||||
Medical condition: Mild to Moderate Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004244-35 | Sponsor Protocol Number: 1/25-03-2014 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:IRCCS Ospedale San Raffaele | |||||||||||||
Full Title: AMYLOID LOAD IN PRODROMAL AD WITH LIMBIC-PREDOMINANT PHENOTYPE PRINCIPAL INVESTIGATOR - STUDIO DEL CARICO DI AMILOIDE IN AD PRODROMICO CON FENOTIPO LIMBICO | |||||||||||||
Medical condition: mild cognitive impairment, Alzheimer's disease prodromal | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004765-32 | Sponsor Protocol Number: ST261-DM-11-005 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | |||||||||||||
Full Title: Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-carnitine Hydrochloride (ST261) Modifi... | |||||||||||||
Medical condition: Mild ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003164-27 | Sponsor Protocol Number: TW001-AD-C2.01 | Start Date*: 2022-06-28 | |||||||||||
Sponsor Name:Treeway TW001AD B.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients | |||||||||||||
Medical condition: Alzheimer´s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000163-89 | Sponsor Protocol Number: COG0104 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a... | |||||||||||||
Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002326-27 | Sponsor Protocol Number: COG0201 | Start Date*: 2022-09-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000445-39 | Sponsor Protocol Number: ACI-24-1801 | Start Date*: 2018-06-19 | |||||||||||
Sponsor Name:AC Immune SA | |||||||||||||
Full Title: A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild ... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001599-12 | Sponsor Protocol Number: 18F-AV-45-C01 | Start Date*: 2014-03-04 |
Sponsor Name:VU University Medical Center (VUmc) | ||
Full Title: The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients | ||
Medical condition: The total number of inclusion in this study is 170 subjects; 140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memor... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004770-28 | Sponsor Protocol Number: ST261-DM-11-006 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | |||||||||||||
Full Title: Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tab... | |||||||||||||
Medical condition: Mild ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Prematurely Ended) LV (Prematurely Ended) DE (Completed) LT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005755-20 | Sponsor Protocol Number: ALZ-801-AD301 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:Alzheon, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype | |||||||||||||
Medical condition: Early Alzheimer’s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005118-37 | Sponsor Protocol Number: H6L-MC-LFAN (e) | Start Date*: 2008-12-15 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo | |||||||||||||
Medical condition: Alzheimers Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000630-30 | Sponsor Protocol Number: AC-AD-003 | Start Date*: 2015-11-26 |
Sponsor Name:AXON NEUROSCIENCE SE | ||
Full Title: “ADAMANT” A 24-months randomised, placebo-controlled, parallel group, double blinded, multi centre, phase 2 study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s ... | ||
Medical condition: Alzheimer’s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) SE (Completed) DE (Completed) SK (Completed) SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013657-14 | Sponsor Protocol Number: AI438006 | Start Date*: 2009-11-10 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
